Report Description Table of Contents What Is the Iliac Stents Market, and How Are Vascular Disease Prevalence and Advanced Stenting Technologies Driving Its Growth? The Global Iliac Stents Market was valued at USD 903.8 million in 2025 and is projected to reach USD 1.46 billion by 2032, growing at a CAGR of 7.14% during 2026–2032, according to Strategic Market Research. Minimally invasive vascular interventions remain central to the market. A 2025 U.S. study involving 2,250 iliac artery stenting patients reported that 94% remained free from major limb-related complications at one year. Japan recorded 2,288 iliac artery stent-grafting procedures in 2024, while UK Hospital Episode Statistics documented more than 23,000 episodes of care involving iliac artery angioplasty or stenting across multiyear review periods. These findings demonstrate established procedural utilization across major healthcare markets. Advances in dedicated venous stents and favorable clinical outcomes are influencing the Iliac Stents Market. A multicenter study involving 162 patients across the United States and Poland reported 90.2% primary venous patency after one year. In 2024, Philips introduced its FDA-approved Duo Venous Stent System, with clinical findings reporting 95.2% one-year patency among patients with nonthrombotic venous obstruction. Established arterial intervention volumes, specialized venous stent technologies, and continued adoption of endovascular treatment remain important to hospitals and vascular specialists. Which Segments Lead the Global Iliac Stents Market, and Which Are Expected to Grow the Fastest? By Type & Product Technology: Why Do Self-Expandable Stents Lead Adoption and Growth? Leading and Fastest-Growing Subsegment: Self-Expandable Stents Self-expandable stents (SES), primarily manufactured from nitinol, play a critical role in the endovascular treatment of iliac artery disease due to their flexibility, shape-memory properties, and ability to accommodate vessel movement. Within the global Iliac Stents Market, self-expandable stents accounted for an estimated 48% market share, equivalent to USD 433.82 million in 2025, and are projected to grow at a CAGR of 7.60% during 2026–2032. Their clinical adoption is supported by effective treatment of long, tortuous iliac artery lesions and sustained vascular patency. By Anatomical Application & Lesion Type: How Do Arterial Lesions and Venous Obstruction Shape Growth? Leading Subsegment: Common Iliac Artery Lesions Common Iliac Artery (CIA) lesions accounted for an estimated 35% of the global Iliac Stents Market, contributing USD 316.33 million in 2025, with a projected CAGR of 6.70% during 2026–2032. Their substantial market presence reflects the widespread use of balloon-expandable and self-expanding stents in aorto-iliac endovascular procedures. Increasing treatment of atherosclerotic narrowing and arterial blockages supports stent utilization, as interventions targeting the common iliac artery help restore blood flow to the lower extremities, improve circulation, and reduce symptoms associated with peripheral artery disease. Fastest-Growing Subsegment: Deep Vein Thrombosis (DVT) / Post-Thrombotic Syndrome Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) are closely associated with iliac vein stenting, particularly in patients experiencing chronic venous obstruction following blood clot formation. Within the global Iliac Stents Market, DVT-related and post-thrombotic iliac vein obstructions accounted for an estimated 12% market share, equivalent to USD 108.46 million in 2025. This category is projected to record the fastest CAGR of 8.70% during 2026–2032, supported by increasing adoption of venous stenting to restore blood flow and relieve persistent symptoms. By Device Material: Why Does Nitinol Lead Iliac Stent Performance and Adoption? Leading and Fastest-Growing Subsegment: Nickel-Titanium (Nitinol) Nitinol-based devices dominated the Iliac Stents Market with an estimated 63% market share, valued at USD 569.39 million in 2025, and are projected to expand at a CAGR of 7.80% during 2026–2032. Nickel-titanium (Nitinol) is widely preferred for self-expanding iliac artery and vein stents due to its shape-memory properties, superelasticity, and flexibility. Its ability to conform to dynamic pelvic anatomy while maintaining consistent vessel support improves stent performance, particularly in anatomically challenging iliac lesions requiring long-term patency and structural durability. By Clinical Indication: How Do New Lesions and Restenosis Shape Intervention Volumes? Leading Subsegment: De Novo Iliac Disease De novo iliac disease accounted for an estimated 69% of the Iliac Stents Market, valued at USD 623.62 million in 2025, and is projected to expand at a CAGR of 7.00% during 2026–2032. De novo iliac disease involves previously untreated atherosclerotic lesions or blockages in the iliac arteries, unlike in-stent restenosis, which occurs within previously implanted stents. Its leading position reflects the widespread use of iliac stents for restoring blood flow, treating arterial narrowing, and improving circulation in patients with peripheral artery disease. Fastest-Growing Subsegment: Restenotic Iliac Disease Restenotic iliac disease accounted for an estimated 21% of the Iliac Stents Market, valued at USD 189.80 million in 2025, and is projected to register the fastest CAGR of 7.80% during 2026–2032. In-stent restenosis (ISR), characterized by recurrent narrowing of the iliac artery following previous stent placement, remains a significant challenge in maintaining long-term vessel patency. Increasing use of repeat endovascular interventions, advanced stent technologies, and improved restenosis management strategies supports sustained growth in iliac artery stenting procedures. By End User: How Are Hospitals and Specialty Clinics Expanding Vascular Treatment? Leading Subsegment: Hospitals & Ambulatory Surgical Centers (ASCs) Hospitals and ambulatory surgical centers accounted for an estimated 88% share of the global iliac stents market, valued at USD 795.34 million in 2025, and are projected to expand at a CAGR of 7.00% during 2026–2032. Hospitals primarily manage complex iliac artery and vein stenting procedures involving advanced imaging, multidisciplinary vascular care, and high-risk patients. Ambulatory surgical centers increasingly support minimally invasive stent placements for stable patients, offering shorter procedural stays, lower treatment costs, and efficient outpatient management of peripheral vascular conditions. Fastest-Growing Subsegment: Specialty Clinics Specialty clinics, including vascular surgery clinics, interventional radiology suites, and advanced vein practices, accounted for an estimated 12% share of the Iliac Stents Market, valued at USD 108.46 million in 2025, and are projected to register the fastest CAGR of 8.00% during 2026–2032. Their expanding role in diagnosing and treating iliac artery and vein disorders is supported by minimally invasive stenting procedures, specialized vascular expertise, advanced imaging capabilities, and coordinated postoperative monitoring, enabling precise stent placement and improved long-term patient outcomes. By Geography: Why Does North America Lead as Asia-Pacific Expands Fastest? Leading Region: North America North America maintained its leading position in the global Iliac Stents Market, accounting for an estimated 39% market share, equivalent to USD 352.48 million in 2025, and is projected to grow at a CAGR of 6.40% during 2026–2032. The region’s dominance reflects its mature healthcare infrastructure, widespread adoption of advanced endovascular procedures, and strong presence of leading stent manufacturers. Increasing treatment of peripheral artery disease, expanding use of minimally invasive iliac interventions, and favorable reimbursement frameworks further support regional market expansion. Fastest-Growing Region: Asia-Pacific Asia-Pacific iliac stents market emerged as a rapidly expanding regional market, accounting for an estimated 24% global market share, valued at USD 216.91 million in 2025, and is projected to register the fastest regional CAGR of 8.90% during 2026–2032. Growth is supported by increasing peripheral artery disease prevalence, expanding access to endovascular interventions, and advancements in minimally invasive vascular procedures. China, India, and Japan are strengthening regional adoption through improving vascular care infrastructure, increasing specialist availability, and wider utilization of self-expanding iliac stents. Which Companies Are Leading the Global Iliac Stents Market, and How Are Their Technologies Strengthening Vascular Treatment? Abbott Laboratories – Advanced Self-Expanding Iliac Artery Stents Abbott maintains an important position in iliac artery interventions through its Absolute Pro Vascular Self-Expanding Stent System, which uses flexible nitinol technology and a tri-axial delivery system for precise positioning. The device supports treatment of narrowed iliac arteries associated with peripheral artery disease. Abbott reports 92.1% primary patency at two years and 98.9% freedom from clinically driven target lesion revascularization at nine months in its cited clinical evidence. Such outcomes support the company's position in arterial stenting, where maintaining long-term circulation and minimizing repeat interventions influence device selection. BD (Becton, Dickinson and Company) – Dedicated Iliac Venous Stenting Technology BD is a prominent participant in iliac venous interventions through its Venovo Venous Stent System, a self-expanding nitinol device designed to treat symptomatic iliofemoral venous outflow obstruction. Its VERNACULAR clinical study evaluated 170 patients across 21 international sites and demonstrated 88.6% weighted primary patency at 12 months and 84.0% estimated primary patency at 36 months. The study also recorded 100% acute technical success, supporting the device's clinical performance in the studied population. BD's venous stent technology addresses treatment needs associated with post-thrombotic syndrome and non-thrombotic iliac vein lesions. W. L. Gore & Associates – Covered Stent Technology for Complex Iliac Arterial Disease W. L. Gore & Associates plays an important role in treating complex aortoiliac arterial disease through its GORE VIABAHN VBX Balloon Expandable Endoprosthesis, which combines a covered stent-graft design with controlled balloon expansion. The technology is used in selected iliac artery lesions, including calcified disease, restenosis, and arterial occlusions. A published five-year clinical follow-up involving 59 patients and 94 treated lesions reported 89.5% primary patency per lesion, 96.1% assisted primary patency, and 89.1% freedom from target lesion revascularization per patient. These outcomes highlight the company's expertise in durable covered stent solutions for challenging iliac anatomy. Other Important Companies and Their Roles Boston Scientific: Developed the VICI Venous Stent System for iliofemoral venous obstruction, with its VIRTUS clinical trial demonstrating 84.0% primary patency at 12 months, supporting its contribution to dedicated venous stenting technologies. Medtronic: Develops the Abre Venous Self-Expanding Stent System for symptomatic iliofemoral venous outflow obstruction, focusing on flexibility, deployment precision, and long-term venous support. Bentley: Specializes in peripheral vascular stent-graft technologies, including the BeGraft product family, supporting endovascular treatment of iliac arterial narrowing and complex vascular anatomy. Analyst Commentary: How Will Lesion-Specific Stents and Outpatient Care Shape Market Growth? The iliac stents market is shifting toward lesion-specific endovascular treatment, with increasing emphasis on dedicated venous stents, flexible nitinol designs, and covered stent technologies. The strongest growth opportunities lie in treating complex iliac artery obstructions, post-thrombotic venous disease, and recurrent vascular narrowing. Improvements in long-term vessel patency, deployment precision, and minimally invasive procedures are expected to accelerate clinical adoption, particularly across Asia-Pacific and expanding outpatient vascular treatment settings. Iliac Stents Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 903.8 Million Revenue Forecast in 2032 USD 1.46 Billion Overall Growth Rate CAGR of 7.14% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Type & Product Technology, By Anatomical Application & Lesion Type, By Device Material, By Clinical Indication, By End User, By Geography By Type & Product Technology Self-Expandable Stents, Balloon-Expandable Stents, Covered Stents (Stent Grafts) By Anatomical Application & Lesion Type Common Iliac Artery Lesions, External Iliac Artery Lesions, Severe Calcified / Complete Obstructive Lesions, May-Thurner Syndrome, Deep Vein Thrombosis (DVT) / Post-Thrombotic Syndrome By Device Material Nickel-Titanium (Nitinol), Cobalt-Chromium & Stainless Steel By Clinical Indication De Novo Iliac Disease, Restenotic Iliac Disease, Iliac Aneurysms and Arterial Injuries By End User Hospitals & Ambulatory Surgical Centers (ASCs), Specialty Clinics By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Growing peripheral artery disease treatment demand, increasing adoption of minimally invasive endovascular interventions, established iliac artery stenting procedures, rising use of self-expanding nitinol stents, growing demand for dedicated iliac venous stents, increasing treatment of May-Thurner syndrome and post-thrombotic venous obstruction, demand for covered stent technologies in complex lesions, and continued need to manage restenotic and obstructive iliac disease Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are supporting growth across the market? A1. Growth is being supported by established iliac stenting volumes, greater use of minimally invasive vascular procedures, and expanding treatment of arterial and venous obstructions. Q2. What technology trends are shaping the industry? A2. The industry is moving toward dedicated venous stents, flexible nitinol platforms, covered stent grafts, and devices designed for better deployment precision and long-term vessel patency. Q3. Why are self-expandable devices important in the market? A3. Self-expandable stents combine flexibility with shape-memory properties, making them suitable for long and tortuous iliac lesions. They accounted for an estimated 48% share in 2025. Q4. Which clinical area is creating the fastest opportunity in the industry? A4. DVT and post-thrombotic syndrome are projected to record the fastest lesion-based CAGR of 8.70% through 2032, supported by increasing use of venous stenting for chronic iliac obstruction. Q5. Why is nitinol gaining preference in the market? A5. Nitinol offers superelasticity, flexibility, and the ability to conform to dynamic pelvic anatomy. These properties support durable vessel scaffolding and make it especially important in self-expanding iliac stent designs. Q6. How are outpatient treatment settings influencing the industry? A6. Specialty clinics and ambulatory facilities are expanding their role in minimally invasive vascular interventions. Their growth reflects shorter procedural stays, specialized imaging capabilities, and increasing outpatient management of eligible patients. Q7. Which region offers the fastest expansion opportunity in the market? A7. Asia-Pacific is projected to record the fastest regional CAGR of 8.90% during 2026–2032. Growth is supported by improving vascular care infrastructure and wider adoption of endovascular procedures across China, India, and Japan. Sources: NIH PubMed – 2025 U.S. Study Evaluated 2,250 Iliac Artery Stenting Patients; 94% Remained Free From Major Adverse Limb Events at One Year, Compared With 83% Following Superficial Femoral Artery Stenting NIH PubMed – Long-Term Outcomes and Major Adverse Limb Events Following Iliac Artery Stenting Japan Surgical Society – 2024 National Clinical Database Recorded 2,288 Iliac Artery Stent-Grafting Procedures, Confirming Established Endovascular Treatment Activity NIH PubMed Central – Japan National Clinical Database 2024 Annual Surgical Report U.S. FDA – Philips Duo Venous Stent System Approved in December 2023 for Symptomatic Iliofemoral Venous Outflow Obstruction; February 2026 Approval Updated Labeling With Final VIVID Study Results FDA – Duo Venous Stent System Premarket Approval and Regulatory Information (P230021) U.S. FDA – Abbott Absolute Pro Self-Expanding Stent Approved for De Novo and Restenotic Common and External Iliac Artery Lesions; Eligible Lesions Extend Up to 90 mm FDA – Absolute Pro Vascular Self-Expanding Stent System Premarket Approval (P110028) Abbott Laboratories – Absolute Pro Self-Expanding Iliac Artery Stent Demonstrated 92.1% Primary Patency at Two Years and 98.9% Freedom From Clinically Driven Target Lesion Revascularization at Nine Months Abbott – Absolute Pro Iliac Stent Clinical Results and Nitinol Self-Expanding Technology BD (Becton, Dickinson and Company) – VERNACULAR Study Involving 170 Patients Across 21 Clinical Sites Demonstrated 88.6% Primary Venous Patency at 12 Months and 84.0% at 36 Months BD – Venovo Venous Stent System, VERNACULAR Clinical Study, and Long-Term Iliac Venous Treatment Outcomes Philips – Duo Venous Stent System VIVID Study Enrolled 162 Patients Across 30 Centers; Achieved 90.2% Primary Patency and 98.7% Freedom From Major Adverse Events at 12 Months Philips – Duo Venous Stent System U.S. Launch and VIVID Clinical Trial Results W. L. Gore & Associates – VIABAHN VBX Covered Iliac Stent Demonstrated 89.5% Five-Year Primary Patency and 96.1% Assisted Primary Patency in a Clinical Follow-Up Study Involving 59 Patients Gore Medical – VIABAHN VBX Balloon-Expandable Stent-Graft Clinical Evidence and Five-Year Outcomes Medtronic – Abre Venous Stent Clinical Study of 200 Patients Demonstrated 81.6% Overall Primary Patency at 36 Months, Including 97.1% for Nonthrombotic Iliac Vein Lesions Medtronic – Abre Venous Self-Expanding Stent System and Three-Year Clinical Results Table of Contents - Global Iliac Stents Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, End User, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, End User, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User Investment Opportunities in the Iliac Stents Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Self-Expandable Stents, Balloon-Expandable Stents, Covered Stents (Stent Grafts), Nitinol-Based Devices, Dedicated Iliac Venous Stents, and Minimally Invasive Endovascular Interventions Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of Iliac Stents in Peripheral Artery Disease Treatment, Iliac Venous Obstruction Management, and Endovascular Vascular Reconstruction Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approval, Clinical Evidence, Reimbursement, and Medical Device Compliance Factors Role of Minimally Invasive Endovascular Interventions, Self-Expandable Stents, Balloon-Expandable Stents, and Covered Stent Technologies in Market Expansion Vascular Patency, Lesion-Specific Device Selection, Deployment Precision, and Postoperative Monitoring Trends in Iliac Stenting Global Iliac Stents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type & Product Technology: Self-Expandable Stents Balloon-Expandable Stents Covered Stents (Stent Grafts) Market Analysis by Anatomical Application & Lesion Type: Common Iliac Artery Lesions External Iliac Artery Lesions Severe Calcified / Complete Obstructive Lesions May-Thurner Syndrome Deep Vein Thrombosis (DVT) / Post-Thrombotic Syndrome Market Analysis by Device Material: Nickel-Titanium (Nitinol) Cobalt-Chromium & Stainless Steel Market Analysis by Clinical Indication: De Novo Iliac Disease Restenotic Iliac Disease Iliac Aneurysms and Arterial Injuries Market Analysis by End User: Hospitals & Ambulatory Surgical Centers (ASCs) Specialty Clinics Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America Iliac Stents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User Country-Level Breakdown: United States Canada Mexico Europe Iliac Stents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific Iliac Stents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America Iliac Stents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User Country-Level Breakdown: Brazil Argentina Rest of Latin America Middle East & Africa Iliac Stents Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User Country-Level Breakdown: GCC Countries Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Abbott Laboratories BD (Becton, Dickinson and Company) W. L. Gore & Associates Boston Scientific Corporation Medtronic plc Bentley InnoMed GmbH Philips Cook Medical Terumo Corporation MicroPort Scientific Corporation Competitive Landscape and Strategic Insights Benchmarking Based on Stent Design, Device Material, Clinical Evidence, Regulatory Approvals, Delivery-System Precision, Vascular Patency, and Regional Presence Supplier Qualification and Medical Device Compliance Capability Analysis Self-Expandable and Balloon-Expandable Stent Positioning Covered Stent-Graft Competitiveness in Complex Iliac Arterial Disease Dedicated Iliac Venous Stenting and Endovascular Treatment Strategy Analysis Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, End User, and Region (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading Iliac Stent Vendors Regulatory Compliance, Clinical Evidence, and Procurement Risk Analysis Technology Adoption Trends Across Self-Expandable Stents, Balloon-Expandable Stents, Covered Stents, Nitinol Devices, and Dedicated Venous Stents List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Type & Product Technology, Anatomical Application & Lesion Type, Device Material, Clinical Indication, and End User (2025 vs. 2032) Global Iliac Stents Ecosystem and Value Chain Analysis